Biogen Finds Clancy’s Replacement, Names Capello New CFO

Xconomy Boston — 

Biogen (NASDAQ: BIIB) has named Jeffrey Capello its new executive vice president and chief financial officer. Capello, a former Boston Scientific (NYSE: BSX), Ortho Clinical Diagnostics, and PerkinElmer (NYSE: PKI) executive, will start on December 11. Biogen has been searching for a CFO ever since Paul Clancy, who spent more than 16 years at the company, left in June to join Alexion Pharmaceuticals (NASDAQ: ALXN).